LOS ANGELES --(BUSINESS WIRE)--Apr. 2, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma
LOS ANGELES --(BUSINESS WIRE)--Feb. 26, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared
LOS ANGELES --(BUSINESS WIRE)--Feb. 23, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m.
LOS ANGELES --(BUSINESS WIRE)--Feb. 12, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, February 26, 2026, following the release of its fourth quarter and full year 2025 financial results.
LOS ANGELES --(BUSINESS WIRE)--Feb. 4, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 3, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 14,750 shares of
LOS ANGELES --(BUSINESS WIRE)--Jan. 7, 2026-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 6, 2026 , the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 10,500 shares of
